FRANLIN LAKES, N.J., Sept. 19,
2017 /PRNewswire/ -- BD (Becton, Dickinson and Company)
(NYSE: BDX), a leading global medical technology company, today
announced the introduction of the BD Ultra-Fine™ micro pen needle
6mm x 32G for use with leading pen injection devices, that is set
for distribution starting September
2017.
With this launch, BD is providing health care practitioners with
an additional needle length option manufactured with BD quality and
reliability to provide a wider variety of needle lengths for people
with diabetes who inject insulin. The introduction of the new pen
needle rounds out the BD Ultra-Fine™ pen needle portfolio, which
now includes 4mm x 32G, 5mm x 31G, 6mm x 32G, 8mm x 31G and 12.7mm
x 29G. BD Ultra-Fine micro 6mm pen needles are covered at the
preferred co-pay by most insurance plans including Medicare part D
and are compatible with leading pen injection
devices.1
"We added the BD Ultra-Fine micro pen needles to ensure BD
has a comprehensive portfolio that provide options to patients and
reinforces BD's commitment to providing the best solutions possible
for people with specific preferences while managing their diabetes
and striving for the best clinical outcomes," said Nabil Shabshab, worldwide president of Diabetes
Care and Digital Health for BD. "This new needle will help ensure
that people with diabetes who prefer a 6mm pen needle will be able
to experience the quality and performance of BD Ultra-Fine pen
needles."
People with diabetes typically inject insulin one or more times
per day into the subcutaneous fat of their abdomen, thigh, upper
arm or buttocks. With shorter needles, including BD Ultra-Fine™
micro pen needles, people with diabetes are less likely to
accidentally inject their insulin dose into a
muscle.2
The BD Ultra-Fine pen needles are designed for a comfortable
injection experience, supporting customer satisfaction and loyalty.
This includes electro-polished, surgical grade needles designed for
smoothness and proprietary micro-bonded needle lubrication for less
friction.* All BD Ultra-Fine pen needles are designed to deliver a
full accurate dose.*
BD will continue to reinforce best practices, including
"shifting to the shortest" available pen needle length. The recent
insulin delivery recommendations published in the September 2016
issue of Mayo Clinic Proceedings indicate that patients
should use the shortest available pen needle, which is
4mm.1,3 BD is committed to promoting better injection
technique through BD's comprehensive educational content.
To review the entire portfolio of BD Ultra-Fine pen needles
please visit (bd.com/Micro), and for more information on the
insulin delivery recommendations published in the Mayo Clinic
Proceedings, visit www.fitter4diabetes.com.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has nearly 50,000 associates
across 50 countries who work in close collaboration with customers
and partners to help enhance outcomes, lower health care delivery
costs, increase efficiencies, improve health care safety and expand
access to health. For more information on BD, please visit
bd.com.
|
|
|
1. BD Pen Needle Compatibility Status Summary with Diabetes Care
& Non-Diabetes Drug Delivery Devices; Documents Number:
149OTH-0004-02 Ver N Dated: 03 July 2017; 10000308903 Ver B Dated:
20 July 2017.
2. Gibney MA, Arce C. Byron K. Hirsch L. Skin and subcutaneous
adipose layer thickness in adults with diabetes at sites used for
insulin injections: implications for needle length recommendations.
Curr Med Res Opin. 2010;26 (6);1519-1530.
3. Frid AH, Kreugel G, Grassi G, et al. New insulin delivery
recommendations. Mayo Clin Proc. 2016;91(9):1231–1255.
*BD pen needles are designed and manufactured to high quality
standards. They are rigorously tested to ensure performance
Requirements. ISO standard 11608-2 has stringent requirements on
needle lubrication, fine needle point assembly and disassembly
torque, dose accuracy testing, needle-to hub engagement and needle
length.
|
Contacts:
|
|
|
|
|
|
|
|
|
|
|
|
Matt
Coppola
|
|
|
|
|
Monique N.
Dolecki
|
BD Public
Relations
|
|
|
|
|
BD Investor
Relations
|
201.847.7370
|
|
|
|
|
201.847.5378
|
matthew_r_coppola@bd.com
|
|
|
|
|
monique_dolecki@bd.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/bd-introduces-new-6mm-pen-needle-for-injection-pens-300521508.html
SOURCE BD (Becton, Dickinson and Company)